|
1
|
Burgess JR and Tucker P: Incidence trends
for papillary thyroid carcinoma and their correlation with thyroid
surgery and thyroid fine-needle aspirate cytology. Thyroid.
16:47–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu X, Groves FD, Mclaughlin CC, Jemal A,
Martin J and Chen VW: Cancer incidence patterns among adolescents
and young adults in the United States. Cancer Causes Control.
16:309–320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coleman MP, Babb P, Damiecki P, Grosclaude
P, Honjo S, Jones J, Knerer G, Pitard A, Quinn MJ, Sloggett A and
De Stavola BL: Cancer survival trends in England and Wales,
1971–1995: deprivation and NHS RegionStudies in Medical and
Population Subjects no. 61. The Stationery Office; London: 1999
|
|
6
|
Schlumberger M and Sherman SI: Approach to
the patient with advanced differentiated thyroid cancer. Eur J
Endocrinol. 166:5–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT,
Lee SL, Mandel SJ, Mazzaferri EL, McIver B, et al: Revised American
Thyroid Association management guidelines for patients with thyroid
nodules and differentiated thyroid cancer. Thyroid. 9:1167–1214.
2009.
|
|
8
|
Luster M, Clarke SE, Dietlein M, Lassmann
M, Lind P, Oyen WJ, Tennvall J and Bombardieri E; European
Association of Nuclear Medicine (EANM), : Guidelines for
radioiodine therapy of differentiated thyroid cancer. Eur J Nucl
Med Mol Imaging. 35:1941–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bodelon C, Polley MY, Kemp TJ, Pesatori
AC, Mcshane LM, Caporaso NE, Hildesheim A, Pinto LA and Landi MT:
Circulating levels of immune and inflammatory markers and long
versus short survival in early-stage lung cancer. Ann Oncol.
24:2073–2079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Budhu A and Xin WW: The role of cytokines
in hepatocellular carcinoma. J Leukoc Biol. 80:1197–1213. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Simonovic SZ, Mihaljevic O, Majstorovic I,
Djurdjevic P, Kostic I, Djordjevic OM and Teodorovic LM: Cytokine
production in peripheral blood cells of patients with
differentiated thyroid cancer: Elevated Th2/Th9 cytokine production
before and reduced Th2 cytokine production after radioactive iodine
therapy. Cancer Immunol Immunother. 64:75–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pluijmen MJ, Eustatia-Rutten C, Goslings
BM, Stokkel MP, Arias AM, Diamant M, Romijn JA and Smit JW: Effects
of low-iodide diet on postsurgical radioiodide ablation therapy in
patients with differentiated thyroid carcinoma. Clin Endocrinol
(Oxf). 58:428–435. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Hou F, Zhang Y, Tian Y, Jiao J,
Ma D, Kong B and Cui B: Changes of Th17/Tc17 and Treg/Th17 cells in
endometrial carcinoma. Gynecol Oncol. 132:599–605. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bailey SR, Nelson MH, Himes RA, Li Z,
Mehrotra S and Paulos CM: Th17 cells in cancer: The ultimate
identity crisis. Front Immunol. 5:2762014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carvalho DFG, Zanetti BR, Miranda L,
Hassumi-Fukasawa MK, Miranda-Camargo F, Crispim JCO and Soares EG:
High IL-17 expression is associated with an unfavorable prognosis
in thyroid cancer. Oncol Lett. 13:1925–1931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henriques A, Inês L, Couto M, Pedreiro S,
Santos C, Magalhães M, Santos P, Velada I, Almeida A, Carvalheiro
T, et al: Frequency and functional activity of Th17, Tc17 and other
T-cell subsets in Systemic Lupus Erythematosus. Cell Immunol.
264:97–103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garcia-Hernandez Mde L, Hamada H, Reome
JB, Misra SK, Tighe MP and Dutton RW: Adoptive transfer of
tumor-specific Tc17 effector T cells controls the growth of B16
melanoma in mice. J Immunol. 184:4215–4227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maruyama T, Kono K, Mizukami Y, Kawaguchi
Y, Mimura K, Watanabe M, Izawa S and Fujii H: Distribution of Th17
cells and FoxP3(+) regulatory T cells in tumor-infiltrating
lymphocytes, tumor-draining lymph nodes and peripheral blood
lymphocytes in patients with gastric cancer. Cancer Sci.
101:1947–1954. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gerloni M and Zanetti M: CD4 T cells in
tumor immunity. Springer Seminars Immunopathol. 27:37–48. 2005.
View Article : Google Scholar
|
|
21
|
Sfanos KS, Bruno TC, Maris CH, Xu L,
Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG:
Phenotypic analysis of prostate-infiltrating lymphocytes reveals
Th17 and treg skewing. Clin Cancer Res. 14:3254–3261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Korn T, Bettelli E, Oukka M and Kuchroo
VK: IL-17 and Th17 cells. Annu Rev Immunol. 27:485–517. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zou W and Restifo NP: T(H)17 cells in
tumour immunity and immunotherapy. Nat Rev Immunol. 10:248–256.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dubin PJ and Kolls JK: Th17 cytokines and
mucosal immunity. Immunol Rev. 226:160–171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fattorossi A, Battaglia A, Ferrandina G,
Buzzonetti A, Legge F, Salutari V and Scambia G: Lymphocyte
composition of tumor draining lymph nodes from cervical and
endometrial cancer patients. Gynecol Oncol. 92:106–115. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Ma D, Tian Y, Wang X, Qiao Y and
Cui B: The imbalance of Treg/Th17 in patients with uterine cervical
cancer. Clin Chim Acta. 412:894–900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rogala E, Nowicka A, Bednarek W,
Barczyński B, Wertel I, Zakrzewski M and Kotarski J: Evaluation of
the intracellular expression of interleukin 17 in patients with
ovarian cancer. Ginekol Pol. 83:424–428. 2012.(In Polish).
PubMed/NCBI
|
|
28
|
Wang RF: Regulatory T cells and innate
immune regulation in tumor immunity. Springer Semin Immunopathol.
28:17–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baier PK, Wolff-Vorbeck G, Eggstein S,
Baumgartner U and Hopt UT: Cytokine expression in colon carcinoma.
Anticancer Res. 25:2135–2139. 2005.PubMed/NCBI
|
|
30
|
Montero AJ, Diaz-Montero CM, Millikan RE,
Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P and Tannir N:
Cytokines and angiogenic factors in patients with metastatic renal
cell carcinoma treated with interferon-alpha: Association of
pretreatment serum levels with survival. Ann Oncol. 20:1682–1687.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mocellin S, Provenzano M, Rossi CR, Pilati
P, Nitti D and Lise M: Use of quantitative real-time PCR to
determine immune cell density and cytokine gene profile in the
tumor microenvironment. J Immunol Methods. 280:1–11. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiang GA, Chen KY, Wang HN and Xiao JF:
Immunological influence of iodine-125 implantation in patients with
hepatocellular carcinoma resection. Nan Fang Yi Ke Da Xue Xue Bao.
30:292–294. 2010.PubMed/NCBI
|
|
33
|
Yang J, Pan T, Du YJ and Zhong X:
Endocrinology Do. Change of CD4+ CD25+ CD127 low regulatory T cells
in peripheral blood of patients with Graves disease treated by 131
I or antithyroid drugs therapy. J Anhui Medicinalis. 5:691–695.
2016.
|
|
34
|
Xue-Qin MA and Shi-Peng YU: Effects of
131I treatment on the IL-23/Th17 axis relevant factor
levels in graves disease patients. Chin J Immunol. 29:R3922013.
|
